Skip to main content
SpringerLink
Log in

Markers and Immunoprofile of Lymphoid Tissue Neoplasms

  • Chapter
  • First Online:
Immunohistochemistry in Tumor Diagnostics

  • 2770 Accesses

Abstract

Lymphoid tissue is a microenvironment composed of B-, T-, and NK-lymphocytes in different maturation and differentiation stages, plasma cells, macrophages, dendritic cells, reticular cells, and granulocytes. For the diagnosis of lymphoma, all these components must be considered. For initial diagnosis, screening markers can be helpful. Further specific markers must be used for the precise diagnosis. Markers listed in different parts of this chapter are essentially used for orientation. The final diagnosis must be done according to the histomorphology, immunophenotype (immunohistochemistry and flow cytometry), and genetic analysis. The 2016 revision of the World Health Organization classification of lymphoid neoplasms was considered in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Higgins RA, Blankenship E, Kinney MC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med. 2008;132:441–61.

    PubMed  Google Scholar 

  2. Zhao XF. Pitfalls in diagnostic hematopathology: part I. Int J Clin Exp Pathol. 2009;2:11–20.

    PubMed  Google Scholar 

  3. Zhao XF. Pitfalls in diagnostic hematopathology: part II. Int J Clin Exp Pathol. 2010;3:39–46.

    CAS  PubMed Central  Google Scholar 

  4. Buresh CJ, Oliai BR, Miller RT. Reactivity with TdT in Merkel cell carcinoma. A potential diagnostic pitfall. Am J Clin Pathol. 2008;129:894–8.

    Article  PubMed  Google Scholar 

  5. Sur M, AlArdati H, Ross C, et al. TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. Mod Pathol. 2007;20:1113–20.

    Article  CAS  PubMed  Google Scholar 

  6. Ordi J, Romagosa C, Tavassoli FA, et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract. A useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol. 2003;2:178–86.

    Article  Google Scholar 

  7. Borscheri N, Roessner A, Röcken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol. 2001;25:1297–303.

    Article  CAS  PubMed  Google Scholar 

  8. Higgins RA, Blankenship JE, Kinney MC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med. 2008;132:441–61.

    PubMed  Google Scholar 

  9. Chu PG, Arber DA, Weiss LM. Expression of T/NK- cell and plasma cell antigens in non-hematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. Am J Clin Pathol. 2003;120:64–70.

    Article  PubMed  Google Scholar 

  10. Sweedlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    Article  Google Scholar 

  11. Masir N, Marafioti T, Jones M, et al. Loss of CD19 expression in B-cell neoplasms. Histopathology. 2006;48:239–46.

    Article  CAS  PubMed  Google Scholar 

  12. Jensen KC, Higgins JPT, Montgomery K, et al. The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms. Mod Pathol. 2007;20:871–7.

    Article  CAS  PubMed  Google Scholar 

  13. Feldman AL, Dogan A. Diagnostic uses of Pax5 immunohistochemistry. Adv Anat Pathol. 2007;14:323–34.

    Article  PubMed  Google Scholar 

  14. Kolhe R, Reid MD, Lee JD, et al. Immunohistochemical expression of PAX5 and TdT by Merkel cell carcinoma and pulmonary small cell carcinoma: a potential diagnostic pitfall but useful discriminatory marker. Int J Clin Exp Pathol. 2013;6(2):142–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Sullivan LM, Atkins KA, LeGallo RD. PAX immunoreactivity identifies alveolar rhabdomyosarcoma. Am J Surg Pathol. 2009;33:775–80.

    Article  PubMed  Google Scholar 

  16. Morgenstern DA, Gibson S, Sebire NJ, Anderson J. PAX5 expression in rhabdomyosarcoma. Am J Surg Pathol. 2009;33:1575–7.

    Article  PubMed  Google Scholar 

  17. Matutes E. New additions to antibody panels in the characterization of chronic lymphoproliferative disorders. J Clin Pathol. 2002;55:180–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Gladkikh A, Potashnikova D, Korneva E, et al. Cyclin D1 expression in B-cell lymphomas. Exp Hematol. 2010;38(11):1047–57.

    Article  CAS  PubMed  Google Scholar 

  19. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1 negative subtype. Haematologica. 2009;94(11):1555–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chen Y-H, Gao J, Fan G, et al. Nuclear expression of Sox11 is highly associated with mantle cell lymphoma but is independent of t(11,14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol. 2010;23:105–12.

    Article  CAS  PubMed  Google Scholar 

  21. Soldini D, Valera A, Sole C, et al. Assessment of SOX11 expression in routine lymphoma tissue sections. Characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma. Am J Surg Pathol. 2014;38:86–93.

    Article  PubMed  Google Scholar 

  22. Ohno H. Pathogenetic role of BCL-6 translocation in B-cell non-Hodgkin’s lymphoma. Histol Histopathol. 2004;19:637–50.

    CAS  PubMed  Google Scholar 

  23. Went PT, Zimpfer A, Pehrs AC, et al. High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia. Am J Surg Pathol. 2005;29(4):474–8.

    Article  PubMed  Google Scholar 

  24. van den Brand M, van Krieken J. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systemic review. Haematologica. 2013;98(7):1003–13.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Faline B, Agostinelli C, Bigerna B, et al. IRTA1 is selectively expressed in nodal and exranodal marginal zone lymphomas. Histopathology. 2012;61(5):930–41.

    Article  Google Scholar 

  26. Younes SF, Beck AH, Ohgami RS, et al. The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including bone marrow. Am J Clin Pathol. 2011;135:697–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Natkunam Y, Sh Z, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood. 2007;109(4):1636–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Gratzinger D, Sh Z, West R, et al. The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol. 2009;131:264–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood. 2005;105(10):3979–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Goteri G, Lucarine G, Zizzi A, et al. Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphoma. Diagn Pathol. 2011;6:97.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Tandon B, Peterson L, Gao J, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol. 2011;24(11):1433–43.

    Article  CAS  PubMed  Google Scholar 

  32. Kermanshahi TR, Jayachandran P, Chang DT, Pai R. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms. Appl Immunohistochem Mol Morphol. 2014;22(10):728–34.

    Article  CAS  PubMed  Google Scholar 

  33. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2010;29:200–2007.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Matutes E. New additions to antibody panels in the characterization of chronic lymphoproliferative disorders. J Clin Pathol. 2002;55:180–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Torlakovic E, Slipicevic A, Florenes V, et al. Fli-1 expression in malignant melanoma. Histol Histopathol. 2008;23:1309–14.

    CAS  PubMed  Google Scholar 

  36. Chu PG, Arber DA, Weiss LM. Expression of T/NK- cell and plasma cell antigens in non-hematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. Am J Clin Pathol. 2003;120:64–70.

    Article  PubMed  Google Scholar 

  37. Nunez AL, Siegal GP, Reddy VVB, et al. CD138 (syndecan-1) expression in bone-forming tumors. Am J Clin Pathol. 2012;137:423–8.

    Article  PubMed  Google Scholar 

  38. Natkunam Y, Warnke RA, Montgomery K, et al. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol. 2001;14:686–94.

    Article  CAS  PubMed  Google Scholar 

  39. Ning S. IRF4 as an oncogenic biomarker for hematological malignancies. J Oncobiomarkers. 2013;1(1):1–6.

    Article  Google Scholar 

  40. Shanks JH, Baneriee SS. VS38 immunostaining in melanocytic lesions. J Clin Pathol. 1996;49:205–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Pileri SA. Follicular helper T-cell related lymphomas. Blood. 2015;126(15):1733–4.

    Article  PubMed  Google Scholar 

  42. Islam A, Vladutiu AO, Donahue T, et al. CD8 expression on B cells in chronic lymphocytic leukemia. A case report and review of the literature. Arch Pathol Lab Med. 2000;124:1361–3.

    CAS  PubMed  Google Scholar 

  43. Tuffaha M. Phenotypic and genotypic diagnosis of malignancies. Immunohistochemical and molecular approach in tumor diagnosis and detection of minimal residual cancer disease. Weinheim, Berlin: Wiley-VCH-Verlag; 2008.

    Book  Google Scholar 

  44. Heim-Hall J, Yohe L. Application of immunohistochemistry to soft tissue neoplasms. Arch Pathol Lab Med. 2008;132:476–89.

    PubMed  Google Scholar 

  45. Kontogianni K, Nicholson AG, Butcher D, Sheppard MN. CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artifact. J Clin Pathol. 2005;58:978–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T- cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30(4):490–4.

    Article  PubMed  Google Scholar 

  47. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin’s lymphoma: the pathologist’s viewpoint. J Clin Pathol. 2002;55:162–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Bayerl MG, Bentley G, Bellan MC, et al. Lacunar and Reed-Sternberg-like cells in follicular lymphomas are clonally related to the centrocytic and centroblastic cells as demonstrated by laser capture microdissection. Am J Clin Pathol. 2004;122:858–64.

    Article  PubMed  Google Scholar 

  49. Tang H, Wei Q, Ge J, et al. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma. Hum Pathol. 2013;44(10):2167–72.

    Article  CAS  PubMed  Google Scholar 

  50. Sotlar K, Cerney-Reiterer S, Petet-Dutter K, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol. 2011;24(4):585–95.

    Article  CAS  PubMed  Google Scholar 

  51. Alimachandani M, Wang ZF, Miettinen M. CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases. Appl Immunohistochem Mol Morphol. 2014;22(5):358–62.

    Article  Google Scholar 

  52. Tong GX, Yee H, Chiriboga L, et al. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol. 2005;36(7):741–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Carl-Thiem-Klinikum, Institut für Pathologie, Cottbus, Germany

    Muin S. A. Tuffaha

  2. Vivantes Klinikum Neukölln, Institut für Pathologie, Berlin, Germany

    Hans Guski

  3. Universität Bonn, UKB, Institut für Pathologie, Bonn, Germany

    Glen Kristiansen

Authors
  1. Muin S. A. Tuffaha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Guski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glen Kristiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Tuffaha, M.S.A., Guski, H., Kristiansen, G. (2018). Markers and Immunoprofile of Lymphoid Tissue Neoplasms. In: Immunohistochemistry in Tumor Diagnostics. Springer, Cham. https://doi.org/10.1007/978-3-319-53577-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53577-7_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-53576-0

  • Online ISBN: 978-3-319-53577-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation